Stanley-Laman Group’s Arbutus Biopharma ABUS Stock Holding History

Stanley-Laman Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,722	Closed	-$90K	–	247
2016 Q2	$90K	Hold	25,722	–	–	0.04%	254
2016 Q1	$106K	Hold	25,722	–	–	0.02%	278
2015 Q4	$114K	Hold	25,722	–	–	0.02%	335
2015 Q3	$157K	Hold	25,722	–	–	0.03%	312
2015 Q2	$305K	Buy	+25,722	New	+$391K	0.06%	246

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stanley-Laman Group's ABUS Position: Q3 2016 in Review

Stanley-Laman Group sold out of Arbutus Biopharma (ABUS) in Q3 2016, closing a stake of 25,722 shares — an estimated $90K sold.

Stanley-Laman Group first reported a position in ABUS in Q2 2015 and held it in 5 quarters. The position peaked at $305K in Q2 2015. 48 funds tracked by Wall St. Rank hold ABUS as of Q3 2016.

Stanley-Laman Group reported no remaining Arbutus Biopharma position as of Q3 2016 after selling out during the quarter.
Stanley-Laman Group sold 25,722 Arbutus Biopharma shares in Q3 2016, an estimated $90K.
Stanley-Laman Group first reported a position in Arbutus Biopharma in Q2 2015 and held it in 5 quarters.
Stanley-Laman Group's Arbutus Biopharma position peaked at $305K in Q2 2015.
48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2016.

Based on Stanley-Laman Group's 13F filing for Q3 2016, filed 28 Oct 2016.